Table 1: Baseline demographics and clinical characteristics on transfer.
| Characteristics | Patients (n = 280) | Male (n = 140) | Female (n = 140) |
| Demographics | |||
| Mean age, years (SD) | 60.10 ± 11.72 | 60.81 ± 10.76 | 59.39 ±12.62 |
| Kuwaitis, n (%) | 206 (73.6%) | 103 (73.6%) | 103 (73.6%) |
| Mean BMI in kg/ m2 | 30.48 ± 7.16 | 26.76 ± 4.36 | 34.14 ± 7.51 |
| Cardiovascular risk factors | |||
| Diabetes Mellitus | 180 (64.3%) | 86 (61.4%) | 94 (67.1%) |
| Hypertension | 200 (71.4%) | 94 (67.1%) | 106 (75.7%) |
| Dyslipidemia | 189 (67.5%) | 91 (65%) | 98 (70%) |
| Smoking | 108 (38.6%) | 82 (58.6%) | 16 (18.6%) |
| Positive family history of coronary artery disease | 101 (36.1%) | 48 (34.3%) | 53(37.9%) |
| H/o Percutaneous coronary intervention (PCI) | 36 (12.9%) | 18 (12.9%) | 18 (12.9%) |
| H/o Coronary Artery Bypass Graft (CABG) | 29 (10.4%) | 17 (12.1%) | 12 (8.6%) |
| Clinical characteristics | |||
| Hemoglobin in gm/ dL- Mean | 13.13 ± 1.86 | 14.04 ± 1.61 | 12.21 ± 1.62 |
| Hemoglobin ˂ 10 gm/dL | 13 (4.64%) | 1 (0.7%) | 12 (8.57%) |
| Creatinine- mean in mmol/ dL | 106.20 ± 106 | 102.21 ± 67.66 | 110.18 ± 106.52 |
| Creatinine > 120 mmol/ dL | 55 (19.64%) | 24 (17.14%) | 31 (22.1%) |
| Fasting Blood Glucose ( mean) in mmol/ dL | 11.70 ± 6.08 | 10.04 ± 4.43 | 13.35 ± 6.98 |
| Fasting Blood Glucose ≥ 7 mmol/ dL | 203 (72.5%) | 96 (68.57%) | 107 (76.43%) |
| Killip class | |||
| Killip I | 80 (28.6%) | 30 (21.4%) | 50 (35.7%) |
| Killip II | 23 (8.2%) | 7 (5%) | 16 (11.4%) |
| Killip III | 118 (42.1%) | 72 (51.4%) | 46 (32.9%) |
| Killip IV | 59 (21.1%) | 31 (22.1%) | 28 (20%) |
| Medications on transfer | |||
| Aspirin | 272 (97.1%) | 138 (98.6%) | 134 (95.7%) |
| Plavix | 262 (93.6%) | 136 (97.1%) | 126 (90%) |
| Beta blockers | 217 (77.5%) | 112 (80%) | 105 (75%) |
| ACE inhibitors | 86 (30.7%) | 38 (27.1%) | 48 (34.3%) |
| Unfractionated heparin | 68 (24.3%) | 37 (26.4%) | 31 (22.1%) |
| Low-molecular-weight heparin | 272 (97.1%) | 138 (98.6%) | 134 (95.7%) |
ACE: Angiotensin-Converting Enzyme Inhibitors; SD: Standard Deviation.